help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2009-0479
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Sharma, A.
Right arrow Articles by Yang, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, A.
Right arrow Articles by Yang, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Endocrinology Vol. 150, No. 9 4278-4286
Copyright © 2009 by The Endocrine Society

The p38 Mitogen-Activated Protein Kinase Regulates 11β-Hydroxysteroid Dehydrogenase Type 2 (11β-HSD2) Expression in Human Trophoblast Cells through Modulation of 11β-HSD2 Messenger Ribonucleic Acid Stability

Anju Sharma, Haiyan Guan and Kaiping Yang

Children’s Health Research Institute and Lawson Health Research Institute, Departments of Obstetrics and Gynaecology and Physiology and Pharmacology, The University of Western Ontario, London, Ontario, Canada N6A 4G5

Address all correspondence and requests for reprints to: Dr. K. Yang, Children’s Health Research Institute, Room A5-132, Victoria Research Laboratories, 800 Commissioners Road East, London, Ontario, Canada N6C 2V5. E-mail: kyang{at}uwo.ca.

The placental 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2; encoded by the HSD11B2 gene) has emerged as a key player in controlling fetal development, but its regulation is incompletely understood. Here we identified p38 MAPK as an important regulator of placental 11β-HSD2. We showed that inhibition of p38 MAPK with the pharmacological inhibitor SB202190 led to an approximately 50% reduction in 11β-HSD2 activity, protein, and mRNA in primary human placental trophoblast cells. Furthermore, the effect of SB202190 was confirmed by the use of two additional p38 inhibitors, SB203580 and SB220025. In addition, SB202190 decreased the half-life of 11β-HSD2 mRNA without altering the HSD11B2 promoter activity, indicating that p38 MAPK regulates placental 11β-HSD2 expression through modulation of 11β-HSD2 mRNA stability. Importantly, small interfering RNA-mediated knockdown of p38{alpha} caused a 50% reduction in 11β-HSD2 activity, suggesting that p38{alpha} is the primary p38 isoform involved. Taken together, these findings suggest a novel pathway controlling placental 11β-HSD2 expression resulting from the activation of p38 MAPK. Given that p38{alpha} is abundantly expressed in the human placenta in which its function is largely unknown, our present study also reveals 11β-HSD2 as an important target through which p38{alpha} may regulate human placental function and consequently fetal growth and development.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society